US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Oncotelic Therapeutics, Inc.

0.0465

-0.0005-1.17%

Volume:39.91K

Turnover:1.92K

Market Cap:20.53M

PE:- -

High:0.0500

Open:0.0500

Low:0.0465

Close:0.0471

52wk High:0.1100

52wk Low:0.0150

Shares:441.58M

Float Shares:214.45M

Volume Ratio:0.10

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

ROE:-23.72%

ROA:-1.57%

PB:2.27

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Oncotelic Therapeutics Issues 1.4 Million Warrants at $0.15 Exercise Price

Oncotelic Therapeutics Awards CEO Restricted Stock Tied to Capital Milestones

Oncotelic Therapeutics Inc - Amends Ica With Jefferson Capital Ventures, on December 31, 2025 - SEC Filing

THOMSON REUTERS

Oncotelic Therapeutics Inc - Amendment Modifies Milestone Threshold to $45 Mln - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OTLC"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OTLC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OTLC\",,,,,undefined,":{"symbol":"OTLC","market":"US","secType":"STK","nameCN":"Oncotelic Therapeutics, Inc.","latestPrice":0.0465,"timestamp":1771621200000,"preClose":0.04705,"halted":0,"volume":39914,"delay":15,"changeRate":-0.011689691817215768,"floatShares":214445090,"shares":441577283,"eps":0,"marketStatus":"Market Closed","change":-0.00055,"latestTime":"02-20 16:00:00 EST Delay","open":0.05,"high":0.05,"low":0.0465,"amount":1921.4,"amplitude":0.074389,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"exchange":"OTCQB","adjPreClose":0.04705,"volumeRatio":0.09569412401434804},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OTLC\",,,,,undefined,":{"symbol":"OTLC","floatShares":214445090,"roa":"-1.57%","roe":"-23.72%","lyrEps":0,"volumeRatio":0.09569412401434804,"shares":441577283,"dividePrice":0,"high":0.05,"amplitude":0.074389,"preClose":0.04705,"low":0.0465,"week52Low":0.015,"pbRate":"2.27","week52High":0.11,"institutionHeld":0,"latestPrice":0.0465,"eps":0,"divideRate":0,"volume":39914,"delay":15,"open":0.05,"prevYearClose":0.0784,"prevWeekClose":0.047,"prevMonthClose":0.0772,"prevQuarterClose":0.0784,"fiveDayClose":0.049,"twentyDayClose":0.0765,"sixtyDayClose":0.0935},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OTLC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-19","symbol":"OTLC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731992400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-08-14","symbol":"OTLC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-05-14","symbol":"OTLC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-04-12","symbol":"OTLC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1712894400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-14","symbol":"OTLC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OTLC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OTLC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OTLC\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607051616","title":"Oncotelic Therapeutics Issues 1.4 Million Warrants at $0.15 Exercise Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2607051616","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607051616?lang=en_us&edition=fundamental","pubTime":"2026-01-30 05:31","pubTimestamp":1769722304,"startTime":"0","endTime":"0","summary":"Oncotelic Therapeutics Inc. has issued 1,422,613 warrants to purchase shares of its common stock at an exercise price of $0.15 per share in connection with a Securities Purchase Agreement with Mast Hill Fund, LP. The warrants are part of a financing arrangement involving a convertible promissory note with a principal amount of $398,333.33. The shares of common stock issuable upon exercise of the warrants have not been registered under the Securities Act of 1933 and may only be offered or sold pursuant to an exemption from registration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieva","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL96f5qX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLC","BK4139"],"gpt_icon":0},{"id":"2606229898","title":"Oncotelic Therapeutics Awards CEO Restricted Stock Tied to Capital Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2606229898","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606229898?lang=en_us&edition=fundamental","pubTime":"2026-01-27 05:31","pubTimestamp":1769463102,"startTime":"0","endTime":"0","summary":"Oncotelic Therapeutics Inc. has entered into a new restricted stock agreement with CEO Dr. Vuong Trieu. Under the agreement, Dr. Trieu is eligible to receive up to 26,512 shares of convertible Series A Preferred Stock, which can be converted into up to 26,512,000 shares of common stock, based on the achievement of four specific performance milestones related to the company’s capital structure. The first milestone, involving the conversion of outstanding 2023 PPM Notes into new 2025 Units, has been achieved, granting Dr. Trieu 4,426 shares of Preferred Stock. Three additional milestones each allow for the vesting of 7,362 shares of Preferred Stock upon completion. The total potential issuance under the agreement represents approximately 4.99% of the company’s outstanding common stock as of the agreement date.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL94Q0PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLC","BK4139"],"gpt_icon":0},{"id":"2601845675","title":"Oncotelic Therapeutics Inc - Amends Ica With Jefferson Capital Ventures, on December 31, 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601845675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601845675?lang=en_us&edition=fundamental","pubTime":"2026-01-07 06:03","pubTimestamp":1767737002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y70DN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLC"],"gpt_icon":0},{"id":"2601456798","title":"Oncotelic Therapeutics Inc - Amendment Modifies Milestone Threshold to $45 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601456798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601456798?lang=en_us&edition=fundamental","pubTime":"2026-01-07 06:03","pubTimestamp":1767737002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y70DN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLC"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/OTLC\",params:#limit:6,delay:false,,,undefined,":[]}}